Trials / Active Not Recruiting
Active Not RecruitingNCT06604949
A Study of Single Dose of LP-003 in Healthy Adult Subjects
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose of LP-003 in Healthy Adult Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Longbio Pharma · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LP-003 200mg | Subcutaneous injection of 200 mg LP-003 |
| DRUG | Placebo | Subcutaneous injection of placebo |
Timeline
- Start date
- 2024-10-23
- Primary completion
- 2026-11-01
- Completion
- 2026-12-01
- First posted
- 2024-09-20
- Last updated
- 2025-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06604949. Inclusion in this directory is not an endorsement.